Home/Esperion Therapeutics/Sheldon L. Koenig
SL

Sheldon L. Koenig

President and Chief Executive Officer

Esperion Therapeutics

Esperion Therapeutics Pipeline

DrugIndicationPhase
NEXLETOL (bempedoic acid)LDL-C lowering in HeFH/ASCVDPhase 4
NEXLIZET (bempedoic acid/ezetimibe)LDL-C lowering in HeFH/ASCVDPhase 4
Bempedoic AcidCardiovascular Outcomes (Primary Prevention)Phase 3
Next-Gen FDCsComprehensive Lipid ManagementDiscovery